[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"updates-archive-2026-08-23-2":3},{"date":4,"filings":5,"has_more":49,"limit":50,"page":51,"total_count":52},"2026-08-23",[6,14,19,27,31,38,42],{"company_name":7,"filing_date":8,"filing_source":9,"headline":10,"id":11,"stock_code":12,"summary_text":13},"Gland Pharma Limited","2026-08-23T09:45:25.209000","NSE","Upcoming Investor Meetings Scheduled","6a8a73fc75683df2585f0014","GLAND","- The company has scheduled one-on-one meetings with institutional investors to discuss its outlook.\n- Meetings are set with Nomura on August 26 and HDFC MF on August 27, 2026.\n- Gland Pharma has stated that no unpublished price-sensitive information will be disclosed during these meetings.",{"company_name":7,"filing_date":15,"filing_source":9,"headline":16,"id":17,"stock_code":12,"summary_text":18},"2026-08-23T09:30:25.153000","Schedules Meetings with Nomura and HDFC MF","6a8a70797132835fab79f25a","• The company has announced its upcoming schedule of one-on-one meetings with institutional investors.\n• A meeting with Nomura is scheduled for August 26, 2026.\n• A meeting with HDFC MF is scheduled for August 27, 2026.\n• This filing is a routine disclosure and does not contain any new material or financial information.",{"company_name":20,"filing_date":21,"filing_source":22,"headline":23,"id":24,"stock_code":25,"summary_text":26},"Quantum Digital Vision India Ltd","2026-08-23T08:05:25.130000","BSE","Shareholders Approve Major Strategic Overhaul at AGM","6a8a5cad7132835fab79f259","530281","• All 12 resolutions proposed at the 46th Annual General Meeting (AGM) were passed with near-unanimous shareholder approval.\n• Key approvals include a potential change of the company's name, an increase in authorised share capital, and an expansion of business activities, signaling a major strategic shift.\n• The company has secured enabling approvals for future acquisitions, investments, and to raise significant debt to fund its growth plans.\n• Mr. Himalay Panna Dassani was re-appointed as Managing Director, and Mrs. Priyanka Pradyumna Tiwari was appointed as a Non-executive Woman Director.",{"company_name":20,"filing_date":21,"filing_source":22,"headline":28,"id":29,"stock_code":25,"summary_text":30},"Shareholders Greenlight Strategic Revamp at 46th AGM","6a8a5ccf166e031b130a7e64","- All 12 resolutions at the 46th Annual General Meeting were passed with nearly 100% shareholder approval.\n- Key approvals include a change in the company's name and an expansion of its main business objectives, signaling a new strategic direction.\n- Shareholders sanctioned an increase in authorized share capital and enhanced borrowing powers to fund future growth and potential M&A.\n- Mr. Himalay Panna Dassani was re-appointed as Managing Director, and Mrs. Priyanka Pradyumna Tiwari was re-appointed as a Director.",{"company_name":32,"filing_date":33,"filing_source":9,"headline":34,"id":35,"stock_code":36,"summary_text":37},"Jubilant Pharmova Limited","2026-08-23T00:50:25.047000","USFDA Approves New Manufacturing Line at US Facility","6a89f6aa5ffc3b421f6fc80e","JUBLPHARMA","*   The company's subsidiary, Jubilant HollisterStier LLC, has received approval from the United States Food and Drug Administration (USFDA).\n*   The approval is for a new \"Isolator based fill and finish line\" (Line 3) at its contract manufacturing facility in Spokane, WA, USA.\n*   This enables the commercial manufacturing of the first product on the new line, significantly boosting the company's sterile injectable CDMO (Contract Development and Manufacturing) business.\n*   This is a key positive development that enhances production capacity, de-risks capital expenditure, and strengthens the company's competitive position in the US market.",{"company_name":32,"filing_date":33,"filing_source":9,"headline":39,"id":40,"stock_code":36,"summary_text":41},"[Receives Key USFDA Approval for US Facility]","6a89f6c8166e031b130a7e63","*   Received approval from the United States Food and Drug Administration (USFDA) for its contract manufacturing facility in Spokane, WA, U.S.A.\n*   The approval is for commercial batch manufacturing of the first product on a new, advanced Isolator based fill and finish line (Line 3).\n*   This milestone significantly strengthens the company's Contract Development and Manufacturing (CDMO) business for sterile injectables.\n*   The facility is operated by its US-based subsidiary, Jubilant HollisterStier LLC.",{"company_name":43,"filing_date":44,"filing_source":9,"headline":45,"id":46,"stock_code":47,"summary_text":48},"Pritish Nandy Communications Limited","2026-08-23T00:00:24.973000","Announces Official Name Change to PNC Media and Entertainment Limited","6a89eaf15ffc3b421f6fc80d","PNC","*   The company has officially changed its name from \"PRITISH NANDY COMMUNICATIONS LIMITED\" to **\"PNC MEDIA AND ENTERTAINMENT LIMITED\"**.\n*   The name change is effective from **August 22, 2026**, following approval from the Registrar of Companies.\n*   This change is administrative and does not affect the company's legal status, rights, or obligations.\n*   The Corporate Identification Number (CIN) and stock exchange symbols (BSE: 532387, NSE: PNC) remain unchanged.",false,100,2,107]